UNSPSC 51271620: Eutectic mixture of local anesthetics

This classification denotes an anesthetic combination drug with the molecular formula C27H42N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 046O35D44R-98PI200987, chemically known as 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;N-(2-methylphenyl)-2-(propylamino)propanamide but generally known as emla or eutectic mixture of local anesthetics, which bears US NIH Compound Identifier 9911821.

SMILES:CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C=CC=C1C)C. Eutectic mixture of local anesthetics bears US NLM identifiers UMLS ID C0059079 and NCI Concept Code C1081.

UNSPSC 51271620 Eutectic mixture of local anesthetics is a Commodity code covering branded and generic local anesthetic formulations sold through state and local government pharmaceutical supply chains. State and local procurement under this code operates primarily through cooperative purchasing vehicles and multistate group purchasing agreements that consolidate demand across participating jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and similar regional cooperative purchasing organizations serve as the primary issuing bodies, sourcing pharmaceutical products for distribution to state agencies, counties, municipalities, school districts, and other public entities that participate in the cooperative agreement. Vendors must supply through established pharmaceutical wholesalers, maintain cGMP certification and Drug Supply Chain Security Act compliance, carry comprehensive insurance coverage, and meet price competitiveness evaluation criteria that heavily weight unit cost.

MMCAP's January 2026 RFP for Generic Multi-Source Pharmaceuticals and OTC Products (Solicitation S1070000015802, due March 26, 2026) represents the primary recent activity under this code and covers Minnesota, Oregon, and other participating states within the cooperative. The solicitation requires vendors to provide detailed product data including National Drug Codes, SKUs, UPCs, and manufacturing locations; maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson); and accept pricing models including flat price, net price formats, or WAC-minus structures. Price competitiveness comprises 75 percent of the evaluation, with fixed pricing, administrative fee compliance, EDI capability, and administrative fee acceptance making up the remaining 25 percent. The contract runs two years for new vendors with optional extensions, or through June 30, 2028 for incumbent responders, with all awarded products required to be available in the marketplace by May 15, 2026, when effective supply begins July 1, 2026.